Zimbabwe has turned down a major US healthcare agreement valued at $367m (£272m) spanning five years due to the United States' insistence on sensitive information.
The decision became public after a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesman later explained that the United States was demanding access to genetic material for scientific study and commercial purposes while was not willing to share the resulting advantages from future vaccines.
"We must now begin the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for further dialogue to find a deal suitable to all parties so the country's vital HIV treatment initiative can proceed.
Broader Background
This rejection comes after a comparable situation in Kenya, where a court suspended a related deal with the US following legal challenges were filed about the security of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government agreements to enhance transparency and responsibility.
According to reports, 16 African countries have to date agreed to these new health pacts, representing more than $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million presently on antiretroviral therapy through American-funded initiatives," Tremont commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that might result from that shared data," he stated.
"Put simply, our nation would supply the raw materials for medical research with no certainty that the final treatments would be accessible to our population should a future disease outbreak arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one health agreements were upending systems already set up through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This framework is designed to ensure that when a country provides its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
These objections over the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation might be designed in a way that honours the independence and dignity of each country."
Health Experts Reaction
Medical experts said it recognised the official position, but urged that negotiations should continue since a large portion of the country's Aids initiatives relied on foreign aid.
"In cases where specific concerns arise, including those relating to data governance or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," it commented.
This impasse highlights the complex debate between accepting vital foreign assistance and protecting a country's data in an ever more data-driven world.